SCD1 is required for EGFR-targeting cancer therapy of lung cancer via re-activation of EGFR/PI3K/AKT signals

被引：0
|
作者：
Kelin She
Shenghua Fang
Wei Du
Xingxing Fan
Jiaxi He
Hui Pan
Liyan Huang
Ping He
Jun Huang
机构：
[1] The First Affiliated Hospital of Guangzhou Medical University,Department of Thoracic Surgery
[2] Guangzhou Research Institute of Respiratory Disease,Department of Thoracic Surgery
[3] China Key Laboratory of Respiratory Disease,Department of Pathology
[4] National Center for Clinical Trials on Respiratory Diseases,undefined
[5] The Central Hospital of Shaoyang City,undefined
[6] Affiliated Cancer Hospital & Institute of Guangzhou Medical University,undefined
[7] Dongguan People’s Hospital,undefined
[8] State Key Laboratory of Quality Research in Chinese Medicine,undefined
[9] Macau Institute for Applied Research in Medicine and Health,undefined
[10] Macau University of Science and Technology,undefined
[11] The First Affiliated Hospital of Guangzhou Medical University,undefined
来源：
Cancer Cell International | / 19卷
关键词：
SCD1; EGFR; AKT; EMT; Lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Gentiopicroside inhibits the progression of gastric cancer through modulating EGFR/PI3K/AKT signaling pathway
    Qishuai Chen
    Tongtong Zhang
    Bingjun Li
    Zhenguo Zhu
    Xiaomin Ma
    Yun Zhang
    Linchuan Li
    Jiankang Zhu
    Guangyong Zhang
    European Journal of Medical Research, 29
  • [22] LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
    Ding, Jianghua
    Ding, Xinjing
    Leng, Zhaohui
    JOURNAL OF CANCER, 2022, 13 (05): : 1837 - 1847
  • [23] Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis
    Deng, Qin-fang
    Fang, Qi-yu
    Ji, Xian-Xiu
    Zhou, Song-wen
    JOURNAL OF CANCER, 2020, 11 (12): : 3667 - 3674
  • [24] Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
    Sarker, Debashis
    Reid, Alison H. M.
    Yap, Timothy A.
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2009, 15 (15) : 4799 - 4805
  • [25] Gentiopicroside inhibits the progression of gastric cancer through modulating EGFR/PI3K/AKT signaling pathway
    Chen, Qishuai
    Zhang, Tongtong
    Li, Bingjun
    Zhu, Zhenguo
    Ma, Xiaomin
    Zhang, Yun
    Li, Linchuan
    Zhu, Jiankang
    Zhang, Guangyong
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2024, 29 (01)
  • [26] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
    Li, Qingfang
    Li, Zhihui
    Luo, Ting
    Shi, Huashan
    MOLECULAR BIOMEDICINE, 2022, 3 (01):
  • [27] PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer
    Xu, Xianping
    Liu, Yu
    Gong, Qiang
    Ma, Le
    Wei, Wei
    Zhao, Linqiong
    Luo, Zhibin
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (02) : 209 - 221
  • [28] FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway
    Yan, Shike
    Zhang, Bing
    Feng, Jingwen
    Wu, Haigang
    Duan, Namin
    Zhu, Yamin
    Zhao, Yueliang
    Shen, Shuang
    Zhang, Kai
    Wu, Wenhui
    Liu, Ning
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [29] Targeting the PI3K signaling pathway in cancer therapy
    Bartholomeusz, Chandra
    Gonzalez-Angulo, Ana Maria
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (01) : 121 - 130
  • [30] Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells
    Akca, Hakan
    Tani, Masachika
    Hishida, Tomoyuki
    Matsumoto, Shingo
    Yokota, Jun
    LUNG CANCER, 2006, 54 (01) : 25 - 33
12345